No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3-antibodies

Seizure

Volumn 15, Issue 5, 2006, Pages 350-354

  Feichtinger, Michael ^a   Wiendl, Heinz ^b   Körner, Eva ^a   Holl, Alexander ^a   Gruber, Lucia ^a   Fazekas, Franz ^a   Schröttner, Oskar ^a   Eder, Hans ^a   Ott, Erwin ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Focal epilepsy; Glutamate receptor type 3 antibodies; Immunomodulative therapy; Intravenous gammaglubulines

Indexed keywords

ANTIBIOTIC AGENT; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; GLUTAMATE RECEPTOR 3; IMMUNOGLOBULIN; PHENYTOIN; RECEPTOR ANTIBODY; VALPROIC ACID;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; COMPLEX PARTIAL SEIZURE; EXPERIENCE; FOCAL EPILEPSY; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; NEUROSURGERY; PRIORITY JOURNAL; SINUSITIS; TEMPORAL LOBE EPILEPSY;

ADOLESCENT; ANTERIOR TEMPORAL LOBECTOMY; AUTOANTIBODIES; EPILEPSY, TEMPORAL LOBE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; RECEPTORS, AMPA;

EID: 33744519309     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.03.002     Document Type: Article

References (14)

1. Palace J., and Lang B. Epilepsy: an autoimmune disease?. J Neurol Neurosurg Psychiatry 69 (2000) 711-714
2. Rogers S.W., Andrews P.I., Gahring L.C., et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 (1994) 648-651
3. Bien C.G., Elger C.E., and Wiendl H. Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis. Expert Opin Investig Drugs 11 (2002) 981-989
4. Leach J.P., Chadwick D.W., Miles J.B., and Hart I.K. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 52 (1999) 738-742
5. Mantegazza R., Bernasconi P., Baggi F., et al. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol 131 (2002) 179-185
6. Wiendl H., Bien C.G., Bernasconi P., et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 57 (2001) 1511-1514
7. Koustova E., Sei Y., Fossom L., et al. LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor. J Clin Invest 107 (2001) 737-744
8. Whitney K.D., and McNamara J.O. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J Neurosci 20 (2000) 7307-7316
9. Roubertie A., Boukhaddaoui H., Sieso V., de Saint-Martin A., Lellouch-Tubiana A., Hirsch E., et al. Antiglial cell autoantibodies and childhood epilepsy: a case report. Epilepsia 46 (2005) 1308-1312
10. Hennessy M.J., Koutroumanidis M., Dean A.F., et al. Chronic encephalitis and temporal lobe epilepsy: a variant of Rasmussen's syndrome?. Neurology 56 (2001) 678-681
11. Ganor Y., Goldberg-Stern H., et al. LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor. Epilepsy Res 65 (2005) 11-22
12. Twyman R.E., Gahring L.C., Spiess J., and Rogers S.W. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 14 (1995) 755-762
13. Andrews P.I., Dichter M.A., Berkovic S.F., et al. Plasmapheresis in Rasmussen's encephalitis. Neurology 46 (1996) 242-246
14. Stangel M., Hartung H.P., Marx P., and Gold R. Epilepsy: an autoimmune disease?. J Neurol Sci 153 (1998) 203-214